Back to All Articles
You must be logged in to create a new articleANDA Litigation Articles
All Articles
Intra-Cellular Therapies Surges 15% Following Settlement of Caplyta ANDA Litigation with Sandoz
Shares of Intra-Cellular Therapies (NASDAQ: ITCI) increased by nearly 15% last week after the company reached a significant settlement with... Read More
Top Attorneys in ANDA Litigation: A Spotlight on the Best Performers and Most Active of 2024
The competitive landscape of ANDA litigation has played a significant role in shaping the pharmaceutical industry, showcasing the legal experts... Read More
Patexia Insight 218: A Deep Dive into the Top Pharmaceutical Companies in ANDA Litigation
In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape... Read More
Introducing the 2024 ANDA Litigation Intelligence Report: Insights into the Competitive Pharmaceutical Landscape
As the pharmaceutical industry continues to face an ever-changing legal environment, staying informed about trends in ANDA litigation has never... Read More
Patexia Insights 215: Benefits and Challenges of Multidistrict Litigations in Hatch-Waxman cases
When several ANDA filers seek approval for the same drug, a branded pharmaceutical company may struggle to bring Hatch-Waxman Act... Read More
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More